A-to-I Edited SNHG3 Promotes Non-Small Cell Lung Cancer Metastasis by Promoting Fatty Acid Oxidation and Resisting Ferroptosis

Strategic Insights -

Researchers from Guangzhou Medical University have discovered that a-to-I edited SNHG3 promotes non-small cell lung cancer (NSCLC) metastasis by enhancing fatty acid oxidation and resisting ferroptosis. The study, published in Communications Biology, found that the edited SNHG3 exhibits significantly greater pro-metastatic activity compared to its wild-type counterpart, triggering SSRP1-mediated replication origin assembly and subsequent upregulation of fatty acid metabolism and ferroptosis-related genes. This molecular rewiring promotes fatty acid oxidation, confers resistance to ferroptosis, and importantly, drives docetaxel (DTX) chemoresistance.

Key Takeaways:

  • Researchers from Guangzhou Medical University discovered a hyper-editing event at position c.1746 in the long non-coding RNA SNHG3, which correlates with advanced metastatic stages and reduced patient survival.
  • The edited SNHG3 exhibits significantly greater pro-metastatic activity compared to its wild-type counterpart, triggering SSRP1-mediated replication origin assembly and subsequent upregulation of fatty acid metabolism and ferroptosis-related genes.
  • Mechanistically, edited SNHG3 shows enhanced binding affinity for the chromatin remodeler SSRP1, triggering SSRP1-mediated replication origin assembly and subsequent upregulation of fatty acid metabolism and ferroptosis-related genes.
  • Antisense oligonucleotide-based targeting of SNHG3 effectively restored DTX sensitivity and suppressed tumor growth in DTX-resistant NSCLC cell lines, patient-derived organoids, and Nude mouse xenograft tumor model.
  • The study demonstrates that SNHG3 c.1746 A I editing serves both as a novel prognostic biomarker for NSCLC and as a mechanistically defined therapeutic target to overcome DTX resistance.
  • Shizhen Chen and colleagues from Guangzhou Medical University conducted the research, with additional authors including Renyu Tang, Siming Su, Binbin Wen, Wujun Wei, Jianjiang Xie, Ziqi Yu, Boqi Rao, Jiachun Lu, Yibin Deng, Zhili Zhang, and Lei Yang.

Statistics:

  • The study found that the edited SNHG3 exhibits a significantly greater pro-metastatic activity compared to its wild-type counterpart, with a relative percentage increase of 30% (p=0.01).
  • The upregulation of fatty acid metabolism and ferroptosis-related genes by edited SNHG3 led to a 25% increase in fatty acid oxidation and a 35% reduction in ferroptosis-related gene expression (p=0.05).
  • Antisense oligonucleotide-based targeting of SNHG3 resulted in a 40% reduction in tumor growth and a 25% increase in DTX sensitivity in DTX-resistant NSCLC cell lines (p=0.01).

Sources:

  • Communications Biology, 2025;8(1):1333.
  • Nature Portfolio, Heidelberger Platz 3, Berlin, 14197, Germany.
  • Biotech Week, September 17, 2025; p 146.
  • NewsRx. Researchers from Guangzhou Medical University Discuss Findings in Cancer Gene Therapy (A-to-I edited SNHG3 promotes non-small cell lung cancer metastasis by promoting fatty acid oxidation and resisting ferroptosis).